PDK1 and amyotrophic lateral sclerosis: These results validate Celecoxib’s role as a multi-target therapeutic agent, prioritizing PDK1 as a focal point for further drug development and clinical investigation in AD and ALS, while also supporting its potential in PD through CASP9 modulation.